Highlights in Resistance Mechanism Pathways for Combination Therapy
Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review...
Main Authors: | João M. A. Delou, Alana S. O. Souza, Leonel C. M. Souza, Helena L. Borges |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/8/9/1013 |
Similar Items
-
The hallmarks of cancer and their therapeutic targeting in current use and clinical trials
by: Samir Al-Bedeary, et al.
Published: (2020-01-01) -
Antitumor Drugs and Their Targets
by: Zlatko Dembic
Published: (2020-12-01) -
β1 integrins as therapeutic targets to disrupt hallmarks of cancer
by: Anne-Florence eBlandin, et al.
Published: (2015-11-01) -
Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives
by: Ulrich T. Hacker, et al.
Published: (2020-07-01) -
CHG: A Systematically Integrated Database of Cancer Hallmark Genes
by: Denan Zhang, et al.
Published: (2020-02-01)